Metabasis Therapeutics Initiates Diabetes Trial
Metabasis Therapeutics, a biopharmaceutical company, has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis’s second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes. The trial is expected to enroll at least 40 patients.
A major milestone was achieved earlier in 2008 with the completion of the Phase IIa, 28-day proof-of-concept trial for MB07803, said Metabasis. This clinical trial provided promising results supporting the potential of MB07803 as an important new approach for treating patients with type 2 diabetes.
MB07803 was shown to be safe and well tolerated at the doses tested in this trial and met its primary efficacy endpoint with results demonstrating a statistically and clinically significant reduction in fasting plasma glucose at day 28. In the current clinical trial, the company is continuing to study higher doses of MB07803 so that the maximal efficacious dose can ultimately be determined.
Paul Laikind, president and CEO of Metabasis, said: “The safety and efficacy results we have seen thus far with MB07803 are encouraging and support our belief that a direct inhibitor of the pathway responsible for the over-production of glucose in patients suffering with diabetes could be an important new therapeutic approach.”